CN110291397A - 肺癌的检测和治疗方法 - Google Patents

肺癌的检测和治疗方法 Download PDF

Info

Publication number
CN110291397A
CN110291397A CN201880010925.0A CN201880010925A CN110291397A CN 110291397 A CN110291397 A CN 110291397A CN 201880010925 A CN201880010925 A CN 201880010925A CN 110291397 A CN110291397 A CN 110291397A
Authority
CN
China
Prior art keywords
ser
thr
pro
antigen
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880010925.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·哈纳希
A·田口
Z·冯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to CN202311117176.0A priority Critical patent/CN117368475A/zh
Publication of CN110291397A publication Critical patent/CN110291397A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Probability & Statistics with Applications (AREA)
  • Physiology (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
CN201880010925.0A 2017-02-09 2018-02-09 肺癌的检测和治疗方法 Pending CN110291397A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311117176.0A CN117368475A (zh) 2017-02-09 2018-02-09 肺癌的检测和治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762456731P 2017-02-09 2017-02-09
US62/456,731 2017-02-09
PCT/US2018/017704 WO2018148600A1 (en) 2017-02-09 2018-02-09 Methods for the detection and treatment of lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311117176.0A Division CN117368475A (zh) 2017-02-09 2018-02-09 肺癌的检测和治疗方法

Publications (1)

Publication Number Publication Date
CN110291397A true CN110291397A (zh) 2019-09-27

Family

ID=63107741

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880010925.0A Pending CN110291397A (zh) 2017-02-09 2018-02-09 肺癌的检测和治疗方法
CN202311117176.0A Pending CN117368475A (zh) 2017-02-09 2018-02-09 肺癌的检测和治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311117176.0A Pending CN117368475A (zh) 2017-02-09 2018-02-09 肺癌的检测和治疗方法

Country Status (8)

Country Link
US (1) US12405274B2 (enExample)
EP (2) EP4528741A3 (enExample)
JP (1) JP7311417B2 (enExample)
KR (2) KR102827354B1 (enExample)
CN (2) CN110291397A (enExample)
CA (1) CA3053116A1 (enExample)
ES (1) ES2995959T3 (enExample)
WO (1) WO2018148600A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112147099A (zh) * 2020-09-22 2020-12-29 范庆坤 一种m蛋白紫外分光检测法
CN115575636A (zh) * 2022-11-22 2023-01-06 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物及其系统
CN116593702A (zh) * 2023-05-11 2023-08-15 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291397A (zh) 2017-02-09 2019-09-27 得克萨斯大学体系董事会 肺癌的检测和治疗方法
CA3146120A1 (en) * 2019-07-29 2021-02-04 Rashid BUX Method of discriminating lung cancer patients
CA3181609A1 (en) * 2020-04-28 2021-11-04 Luxembourg Institute Of Health (Lih) Biomarkers for detection of lung cancer
WO2022051753A1 (en) * 2020-09-01 2022-03-10 Oncodea Corporation Predictive diagnostic test for early detection and monitoring of diseases
WO2022072471A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
EP4357782A1 (en) * 2022-10-18 2024-04-24 MU Bioteknik Aktiebolag Protein biomarker panel for the diagnosis of colorectal cancer
CN118983078B (zh) * 2024-08-15 2025-03-25 立本医疗器械(成都)有限公司 基于ptr-tof-ms的肺癌筛查模型构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321760A (zh) * 2011-08-26 2012-01-18 泸州医学院附属医院 一种非小细胞肺癌标志物及应用
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
US20130196868A1 (en) * 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
CN105717146A (zh) * 2016-03-29 2016-06-29 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2606015T3 (es) * 2005-12-22 2017-03-17 Abbott Molecular Inc. Métodos y combinaciones de marcadores para la detección de la predisposición al cáncer de pulmón
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EP2515116A1 (en) * 2007-05-18 2012-10-24 Duke University Serum biomarkers for the early detection of lung cancer
JP2013525814A (ja) * 2010-05-07 2013-06-20 アッヴィ・インコーポレイテッド 標的化チロシンキナーゼインヒビターでの治療に対する感受性の予測方法
WO2011150974A1 (en) 2010-06-03 2011-12-08 Porto Conte Ricerche S.R.L. Biomarkers for lung neuroendocrine tumors
US20140271453A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US9753037B2 (en) * 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150072890A1 (en) * 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) * 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer
CN108139381A (zh) 2015-06-26 2018-06-08 百奥马克癌症系统公司 肺癌检测方法
JP6903672B2 (ja) 2016-03-08 2021-07-14 マグアレイ，インコーポレイテッド 肺癌の診断および治療のための蛋白質と自己抗体バイオマーカー
CN110291397A (zh) 2017-02-09 2019-09-27 得克萨斯大学体系董事会 肺癌的检测和治疗方法
WO2022072471A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
CN102321760A (zh) * 2011-08-26 2012-01-18 泸州医学院附属医院 一种非小细胞肺癌标志物及应用
US20130196868A1 (en) * 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
CN105717146A (zh) * 2016-03-29 2016-06-29 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DON D. SIN 等: "Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction", 《JOURNAL OF CLINICAL ONCOLOGY》 *
LYNNETTE FERNANDEZ-CUESTA 等: "Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer", 《EBIOMEDICINE》 *
WILLIAM R. WIKOFF 等: "Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non–Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112147099A (zh) * 2020-09-22 2020-12-29 范庆坤 一种m蛋白紫外分光检测法
CN115575636A (zh) * 2022-11-22 2023-01-06 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物及其系统
CN116593702A (zh) * 2023-05-11 2023-08-15 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统
CN116593702B (zh) * 2023-05-11 2024-04-05 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统

Also Published As

Publication number Publication date
US20200025766A1 (en) 2020-01-23
WO2018148600A1 (en) 2018-08-16
KR102630885B1 (ko) 2024-01-29
CA3053116A1 (en) 2018-08-16
EP4528741A2 (en) 2025-03-26
KR102827354B1 (ko) 2025-06-30
KR20240015172A (ko) 2024-02-02
JP2020510816A (ja) 2020-04-09
US20230314436A1 (en) 2023-10-05
EP4528741A3 (en) 2025-04-09
EP3580560A4 (en) 2020-12-09
ES2995959T3 (en) 2025-02-11
EP3580560B1 (en) 2024-10-02
JP7311417B2 (ja) 2023-07-19
KR20190116368A (ko) 2019-10-14
US12405274B2 (en) 2025-09-02
CN117368475A (zh) 2024-01-09
EP3580560A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
JP7311417B2 (ja) 肺癌の検出および処置のための方法
Faca et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development
Jahan et al. Trefoil factor (s) and CA19. 9: a promising panel for early detection of pancreatic cancer
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
Yang et al. Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
WO2016094330A2 (en) Methods and machine learning systems for predicting the liklihood or risk of having cancer
JP2011523049A (ja) 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー
Haab et al. Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens
Marmor et al. Biomarkers in lung cancer screening: a narrative review
JP2020514689A (ja) 膵管腺癌の検出および処置のための方法
Basso et al. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
Wu et al. Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery
Di Noia et al. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Li et al. Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
Ye et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
Jannawan et al. High level of serum coiled-coil domain containing 25 (CCDC25) as a diagnostic marker for cholangiocarcinoma but not for other cancers
Yu et al. Elevated serum megakaryocyte potentiating factor as a predictor of poor survival in patients with mesothelioma and primary lung cancer
Xiong et al. Protein expression profiling identifies a prognostic model for ovarian cancer
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
Lu et al. Auxiliary diagnosis of lung cancer on the basis of a serum protein biomarker panel
Wang et al. STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
He et al. Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas
US12504430B2 (en) Methods for the detection and treatment of lung cancer
Wang et al. Lower expression of MMP2, FLNA, and CFL1 is correlated with favorable prognosis in invasive micropapillary breast cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190927

RJ01 Rejection of invention patent application after publication